SY
Syncom Formulations (India) Ltd (SYNCOMF)
₹21.90
Mkt cap
₹2,059 Cr
P/E ratio
22.00
P/B
4.42
Div yield
0.46%
ROE
17.60%
ROCE
24.80%
EPS (TTM)
₹1.00
Book value
₹5
52W range
10–27
Sector
Healthcare
Price history
Previous close
Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered. [1]
NSE SYNCOMFBSE 524470
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−20.33% from high₹22
₹10+114.50% from low₹27
Current
₹21.90
Prev close
₹22.09
Day
−0.86%
Price performance
1D
−1.31%
1W
+7.44%
1M
−1.27%
3M
+41.01%
6M
+52.88%
1Y
+31.48%
YTD
+51.45%
Financials
Revenue, profit & margin
P/E ratio
22.0×
SYNCOMF is 32% below the sector median of 32.5×
SYNCOMF22.0×
Sector median32.5×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 62 | 63 | 73 | 87 | 101 | 127 | 148 | 117 | 121 | 115 | 134 | 125 | 137 | |
| YoY Sales growth | +14% | +10% | +19% | +46% | +63% | +101% | +103% | +34% | +20% | -10% | -10% | +7% | +13% | |
| Expenses | 56 | 57 | 64 | 76 | 90 | 112 | 131 | 101 | 103 | 93 | 113 | 99 | 106 | |
| Operating Profit | 6 | 7 | 9 | 10 | 12 | 15 | 17 | 16 | 19 | 21 | 21 | 26 | 30 | |
| OPM % | 10% | 11% | 12% | 12% | 12% | 11% | 12% | 14% | 15% | 18% | 16% | 21% | 22% | |
| Other Income | 4 | 4 | 3 | 1 | 4 | 4 | 7 | 6 | 5 | 5 | 14 | 8 | 6 | |
| Interest | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | |
| Profit before tax | 8 | 9 | 9 | 10 | 15 | 17 | 23 | 20 | 22 | 25 | 33 | 32 | 34 | |
| Tax % | 24% | 25% | 27% | 24% | 25% | 24% | 24% | 22% | 25% | 25% | 25% | 23% | 26% | |
| Net Profit | 6 | 6 | 7 | 8 | 11 | 13 | 18 | 16 | 17 | 19 | 25 | 25 | 25 | |
| EPS in Rs | 0.07 | 0.07 | 0.07 | 0.08 | 0.12 | 0.14 | 0.19 | 0.17 | 0.18 | 0.20 | 0.26 | 0.26 | 0.27 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Sep 202650.57%Promoter
Promoters50.57%
FIIs2.23%1.88
Public47.20%1.87
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,884.90 | 36.76 | 4,52,251 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,180.50 | 86.86 | 2,96,807 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,689.50 | 82.16 | 1,78,374 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,294.60 | 92.53 | 1,23,980 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,200.00 | 26.42 | 1,19,700 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,390.20 | 41.47 | 1,16,119 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,415.00 | 36.81 | 1,14,316 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Syncom Formul. | ₹21.90 | 22.04 | 2,059 | 0.46% | 25 | +50.83% | 137 | +12.53% | 24.78% |
| Median: 160 Co. | ₹432.20 | 32.47 | 1,983 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 14 Nov - Submission of Press Clipping regarding publication of extract of Unaudited Standalone and Consolidated Financial Results for the Quarter/Half Year ended on 30th September, 2026Submission Of Standalone & Consolidated Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September, 2026, Pursuant To Regulation 33(3) Of The SEBI (LODR) Regulations, 2015 13 Nov - Syncom Formulations posted Q2 FY27 unaudited standalone and consolidated results on 13 November 2026.Board Meeting Outcome for Submission Of Standalone & Consolidated Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September, 2026, Pursuant To Regulation 33(3) Of The SEBI (LODR) Regulations, 2015. 13 Nov - Syncom Formulations approved Q2/H1 FY27 unaudited results; standalone PAT Rs 49.98 crore, consolidated PAT Rs 51.50 crore.Board Meeting Intimation for Corporate Announcement U/R 29(1)(A) Of SEBI (LODR) Regulations, 2015 Read With SEBI (PIT) Regulations, 2015 Regarding Intimation Of Holding The 3/2026-27 Board Meeting Scheduled To Be Held On Friday, 13Th Day Of November, 2026 4 Nov - Board meeting on 13 Nov 2026 to approve Q2 FY27 unaudited results and related statements.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Oct - Certificate for Compliance of Regulation 74(5) of the SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended 30th September, 2026.






